Serious Noncompliance Section
A Serious Noncompliance section addresses escalation and response when noncompliance materially threatens participant protection or reliable results. It is not a duplicate of Protocol Deviations, which covers departures from planned conduct more generally.
A Serious Noncompliance section explains how potentially material noncompliance is identified, escalated, investigated, corrected, and reported to the appropriate parties when required.
Key details
Important caveats
Scope Boundary
Classification and reporting thresholds vary by governing regulation and ethics/IRB requirements. Do not label every protocol deviation “serious noncompliance,” and do not state universal reporting timelines.
Further guidance
Content
Describe triggers for escalation, responsible roles, root-cause analysis, corrective/preventive actions, follow-up for adequacy, and notification pathways where applicable.
Purpose
Separate material compliance failures from routine operational variation so escalation is proportionate and traceable.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities